데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
101626-70-4C=CCN1CCc2nc(N)sc2CC1DHSSDEDRBUKTQY-UHFFFAOYSA-N101626-70-4DTXSID8046321CHEMBL279085CHEBI:93327개요Domin was launched in Japan for Parkinson's disease. The compound is readily accessible in two steps from I-allylhexahydro-4H-azepin4-one. Its antiparkinson activity resides in the fact that talipexole is a selective agonist for presynaptic dopamine D2 receptors with no D1 receptor activity. It is a clonidine-like α2-adrenoreptor agonist and has fewer GI side effects than bromocriptine the most widely used dopamine angonist. Also it is 70 times more potent than bromocriptine and has a more rapid onset of action. In addition to its anti-tremor activity there was a sedative effect but no emesis. The latter probably a result of talipexole's 5-HT3 receptor antagonistic activity. Its metabolites have no biological activity, there was no development of tolerence and its effect could be enhanced by L-dopa.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…